Roles of BCL-2 and MDR1 expression in the efficacy of paclitaxel-based lung cancer chemoradiation.

Abstract

BACKGROUND:

The associations between B-cell lymphoma 2 (BCL-2) and multi-drug resistance associated P-glycoprotein (MDR1) expressions and chemoradiotherapy outcome of patients with non-small cell lung cancer (NSCLC) were analysed.

PATIENTS AND METHODS:

Thirty-two NSCLC patients were treated with paclitaxel-based chemoradiotherapy. The tumour expressions of BCL-2 and MDR1 were analysed by means of immunohistochemistry with regard to the clinical response and survival data.

RESULTS:

Partial remission and stable disease were achieved in 19 (59%) and 10 (31%) cases, respectively. Significant differences in progression-free survival were observed between responders and non-responders (13.7 vs. 6.0 months, p=0.028), and between patients with or without a gross tumour volume (GTV) shrinkage (GTV(>50) 13.7 vs. 6.0 months, p=0.009). Overexpression of BCL-2 and of MDR1 was observed in 6 (21.4%) cases each. Overexpression of both markers together was associated with poor response (GTV reduction: p=0.005; RECIST: p=0.023) and lower progression-free survival (overexpression of both, low expression of both, mixed: 3.1, 13.4, 4.1 months, respectively, p<0.001).

CONCLUSION:

BCL-2 and MDR1 overexpression may predict the inefficacy of paclitaxel-based chemoradiotherapy.

• Authors: Anikó Maráz, József Furák, Regina Pálföldi, József Eller, Erika Szántó, Zsuzsanna Kahán, László Thurzó, József Molnár, László Tiszlavicz, Katalin Hideghéty
• Journal: Anticancer research (Anticancer Res) Vol. 31 Issue 4 Pg. 1431-6 (Apr 2011) ISSN: 1791-7530 [Electronic] Greece
• PMID: 21508398 (Publication Type: Journal Article)

Chemical References

• ABCB1 protein, human
• ATP Binding Cassette Transporter, Subfamily B
• ATP Binding Cassette Transporter, Subfamily B, Member 1
• Proto-Oncogene Proteins c-bcl-2
• Taxoids
• Deoxycytidine
• Docetaxel
• Carboplatin
• Paclitaxel
• Cisplatin
• Gemcitabine

Topics

• ATP Binding Cassette Transporter, Subfamily B
• ATP Binding Cassette Transporter, Subfamily B, Member 1 (metabolism)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Carboplatin (administration & dosage)
• Carcinoma, Non-Small-Cell Lung (metabolism, secondary, therapy)
• Cisplatin (administration & dosage)
• Deoxycytidine (administration & dosage, analogs & derivatives)
• Docetaxel
• Drug Resistance, Multiple
• Drug Resistance, Neoplasm
• Female
• Humans
• Immunoenzyme Techniques
• Lung Neoplasms (metabolism, secondary, therapy)
• Male
• Middle Aged
• Paclitaxel (administration & dosage)
• Prospective Studies
• Proto-Oncogene Proteins c-bcl-2 (metabolism)
• Radiotherapy Dosage
• Survival Rate
• Taxoids (administration & dosage)
• Treatment Outcome
• Gemcitabine